In the third quarter of the fiscal year ending March 2026, Shionogi & Co., Ltd. achieved revenue of 360.7 billion yen (8.1% YoY increase), operating income of 148.7 billion yen (15.1% YoY increase), and quarterly profit of 158.2 billion yen (18.7% YoY increase), realizing growth in both revenue and profit.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4507-20260130-01.pdf","jir_short_summary":"In the third quarter of the fiscal year ending March 2026, Shionogi & Co., Ltd. achieved revenue of 360.7 billion yen (8.1% YoY increase), operating income of 148.7 billion yen (15.1% YoY increase), and quarterly profit of 158.2 billion yen (18.7% YoY increase), realizing growth in both revenue and profit.","jir_summary":"### Overview of Performance\nIn the third quarter of the fiscal year ending March 2026, Shionogi & Co., Ltd. reported revenue of 360.7 billion yen (8.1% YoY increase), operating income of 148.7 billion yen (15.1% YoY increase), and quarterly profit of 158.2 billion yen (18.7% YoY increase). The revenue growth was primarily driven by increased domestic prescription pharmaceutical sales (+7.8 billion yen), growth in overseas subsidiaries\/exports (+5.6 billion yen), and increased royalty income (+14.5 billion yen). The rise in operating income resulted from improved profitability that offset increases in selling, general and administrative expenses (including sales-related expenses in the U.S. business and consolidation of Torii Pharmaceutical). Quarterly profit also saw significant year-over-year growth.\n\n### Segment Performance and Financial Position\nDomestic prescription pharmaceuticals performed well at 86.7 billion yen (9.8% YoY increase), overseas subsidiaries\/exports at 48.9 billion yen (12.8% YoY increase), and royalty income at 201.3 billion yen (7.8% YoY increase). The consolidation of Torii Pharmaceutical as a subsidiary and the absorption-type split of JT Pharmaceutical business led to increases in goodwill and intangible assets, resulting in total assets of 1.728 trillion yen, up 192.6 billion yen from the end of the previous fiscal year. Liabilities also increased, but equity attributable to owners of the parent rose to 1.5142 trillion yen. Capital expenditures increased 17.3% YoY to 11.2 billion yen, with research and development expenses also trending upward to 82.3 billion yen.","jir_financial_highlights":"Revenue: 360.7 billion yen (YoY change 8.1%)\nOperating Income: 148.7 billion yen (YoY change 15.1%)\nNet Income Attributable to Owners of Parent: 158.2 billion yen (YoY change 18.3%)\nRevenue Full-Year Forecast for FY2025: 500.0 billion yen (Progress Against Forecast 72.1%)\nOperating Income Full-Year Forecast for FY2025: 185.0 billion yen (Progress Against Forecast 80.4%)\nNet Income Attributable to Owners of Parent Full-Year Forecast for FY2025: 188.0 billion yen (Progress Against Forecast 84.2%)","jir_category":"","jir_hashtags":"#ShionogiCoLtd, #SupplementaryFinancialMaterials, #JapaneseStocks","jir_key_figures":"Revenue: 360.7 billion yen (8.1% YoY increase)\nOperating Income: 148.7 billion yen (15.1% YoY increase)\nNet Income Attributable to Owners of Parent: 158.2 billion yen (18.3% YoY increase)","jir_meta_title":"Shionogi & Co., Ltd. Supplementary Materials for Q3 FY March 2026 Financial Results Revenue 360.7 Billion Yen Operating Income 148.7 Billion Yen","jir_meta_description":"Supplementary materials for the Q3 FY March 2026 financial results of Shionogi & Co., Ltd. Revenue increased 8.1% YoY to 360.7 billion yen, operating income rose 15.1% to 148.7 billion yen, and quarterly profit grew 18.7% to 158.2 billion yen, achieving both revenue and profit growth.","jir_og_title":"Shionogi & Co., Ltd. Q3 FY 2026 Supplementary Financial Results Released","jir_og_description":"Detailed report on the performance for Q3 FY March 2026. Revenue of 360.7 billion yen, operating income of 148.7 billion yen, and quarterly profit of 158.2 billion yen with growth in both revenue and profits.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Revenue Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Apr-Jun 2024\\\",\\\"Jul-Sep 2024\\\",\\\"Oct-Dec 2024\\\",\\\"Jan-Mar 2025\\\",\\\"Apr-Jun 2025\\\",\\\"Jul-Sep 2025\\\",\\\"Oct-Dec 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (billion yen)\\\",\\\"data\\\":[976,1164,1196,1047,998,1132,1477],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Operating Income Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Apr-Jun 2024\\\",\\\"Jul-Sep 2024\\\",\\\"Oct-Dec 2024\\\",\\\"Jan-Mar 2025\\\",\\\"Apr-Jun 2025\\\",\\\"Jul-Sep 2025\\\",\\\"Oct-Dec 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (billion yen)\\\",\\\"data\\\":[281,478,534,274,351,397,740],\\\"borderColor\\\":\\\"#8e5ea2\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Business Segment April-December 2025\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Prescription Pharmaceuticals\\\",\\\"Overseas Subsidiaries\/Exports\\\",\\\"Contract Manufacturing\\\",\\\"OTC Pharmaceuticals\\\",\\\"Royalty Income\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (billion yen)\\\",\\\"data\\\":[867,489,102,117,2013,19],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\",\\\"#3cba9f\\\",\\\"#e8c3b9\\\",\\\"#c45850\\\",\\\"#f4a261\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"profit_margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Margin Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Apr-Jun 2024\\\",\\\"Jul-Sep 2024\\\",\\\"Oct-Dec 2024\\\",\\\"Jan-Mar 2025\\\",\\\"Apr-Jun 2025\\\",\\\"Jul-Sep 2025\\\",\\\"Oct-Dec 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Margin (%)\\\",\\\"data\\\":[28.8,35.5,38.7,35.7,35.2,35.1,41.2],\\\"borderColor\\\":\\\"#ff6384\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true,\\\"max\\\":50}}}}\"}, {\"jir_chart_id\": \"financial_position_assets\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-End Total Assets Trends\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"End of March 2025\\\",\\\"End of December 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Total Assets (billion yen)\\\",\\\"data\\\":[15353,17280],\\\"backgroundColor\\\":[\\\"#3e95cd\\\",\\\"#8e5ea2\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-22161","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n